Ozempic & Wegovy Lawsuits

Users of the weight-loss and diabetes medications Ozempic and Wegovy are filing lawsuits claiming the drugs may have caused serious and permanent medical complications. If you used Ozempic or Wegovy and experienced one of the linked injuries, you may be eligible for compensation.

Quick Facts

Category

Detail

Lawsuit Status

Active — mass tort / multi-district litigation underway

Product Name

Ozempic, Wegovy

Defendant(s)

Novo Nordisk (manufacturer) and possibly others

Potential Compensation

Varies significantly based on injury severity and case details

Deadline to File

TBD — dependent on state statute of limitations

What is the Ozempic & Wegovy Lawsuit About?

These lawsuits center on allegations that the drugs Ozempic and Wegovy (both containing the active ingredient semaglutide) can lead to severe injuries such as gastrointestinal damage, stomach paralysis (gastroparesis), intestinal blockages and even vision loss.
Plaintiffs claim the manufacturer knew or should have known about these risks and failed to adequately warn patients and health-care providers, prioritizing sales over safety.
In short: they argue the companies marketed these drugs without fully disclosing potentially life-changing side-effects.

Who Qualifies for This Lawsuit?

You may qualify to join the Ozempic/Wegovy lawsuits if:

  • You used Ozempic or Wegovy (or another semaglutide‐containing GLP-1 drug)

  • You developed one of the qualifying serious injuries (e.g., gastroparesis, intestinal blockage, vision loss) after using the drug

  • You have medical records showing drug use and injury diagnosis

  • You are within your state’s legal time window to file

Injuries or Damages Reported

 

Lawsuits have identified a number of potential harms linked to prenatal acetaminophen use, including:

  • Autism spectrum disorder (ASD)

     

  • Attention-deficit/hyperactivity disorder (ADHD)

     

  • Behavioural and developmental disorders

     

  • Long-term educational or support needs

     

  • Emotional and financial stress on the family
2022–2023
Gastrointestinal Effect

Reports begin to mount of gastrointestinal and intestinal issues linked to GLP-1 drugs such as Ozempic and Wegovy.

 

2023

At least 55 lawsuits consolidated into a federal MDL (multidistrict litigation) in the Eastern District of Pennsylvania.

2024

Discovery and legal proceedings advance; plaintiffs’ legal teams begin gathering internal manufacturer documents, testing data and risk warnings.

 

2024-2025

Further cases filed in state courts; more potential injuries come to light (e.g., vision loss) and legal pressure increases.

2025-2026

Trials and settlement discussions expected to intensify; individuals are being encouraged to act quickly to protect their rights.

How to File a Claim

Filing a claim is simple and confidential:

  1. Fill out the short form below

  2. A participating class action attorney will review your situation

  3. If you qualify, they’ll file your claim and guide you through the process

You pay nothing upfront — you only pay if compensation is awarded

  • It can be. While some users recover after stopping the drug, many plaintiffs allege they suffer from permanent gastroparesis, meaning they continue to vomit daily and have difficulty eating months or even years after quitting the medication. This long-term suffering is a key factor in calculating potential settlement amounts.

  • Recent studies (including one from Harvard Medical School) have found a potential link between semaglutide (the active ingredient in Ozempic/Wegovy) and a condition called NAION, which causes sudden, painless, and often permanent blindness in one eye. This is a newer claim in the lawsuits but is being taken very seriously.

  • No. The FDA has not issued a recall. However, they have required label updates to include warnings about intestinal blockages (ileus). The lawsuit argues these warnings came too late and still don't fully explain the risks of permanent stomach paralysis or blindness.

  • This is complicated. The current major lawsuits are against Novo Nordisk (the brand name manufacturer). If you used a generic "compounded" version from a local wellness spa or online pharmacy, you might have a different type of claim. It is best to submit your details so a lawyer can review your specific situation.

  • No. As of early 2025, the cases are consolidated in a federal MDL (Multidistrict Litigation) in Pennsylvania. The "Bellwether trials" (test trials) are expected to begin in late 2025 or 2026. This process takes time, which is why starting your claim with Class Action Winning sooner rather than later is critical to ensure you are in line when settlements are negotiated.

  • Gallbladder removal (cholecystectomy) was one of the earlier claims associated with these drugs. While some firms are still accepting these cases, the litigation has shifted heavily toward Gastroparesis and Obstruction injuries. A lawyer can tell you if your specific gallbladder claim is still viable.

"I used Wegovy for weight-loss thinking it was safe. When I was hospitalised for a bowel blockage I finally realised something was seriously wrong. Class Action Winning helped me find out I might have a claim — I’m so glad I reached out."

Michelle T.
California

 “After being prescribed Ozempic for diabetes my vision started deteriorating fast. I felt alone and ignored. Class Action Winning explained what was happening, and matched me with a lawyer who understood these GLP-1 drug risks. Finally, someone is listening.”

Robert G.
Texas

 “I had chronic stomach issues after starting Wegovy, but no one told me it could be this. This site gave me clarity and hope. The process was simple, and I didn’t feel pressured — just empowered.”

Ella P.
Florida

 “What started as a simple injection for weight-loss turned into a nightmare of emergency surgery and long-term health problems. Class Action Winning was the beacon of help we needed.”

James M.
Illinois
25431